A Drug to Fertilize Schering-Plough's Growth?

Down 20% so far this year, Schering-Plough (NYSE: SGP  ) needs something to replace all those cholesterol-fighting Vytorin and Zetia prescriptions (and revenue) that it and Merck (NYSE: MRK  ) are expected to lose. Yesterday, the company announced results of a trial for a drug that could help Schering take a few steps on the road to recovery.

In a phase 3 trial, the drugmaker's corifollitropin alfa was at least as good at helping women undergoing fertility treatments to get pregnant as its currently available treatment, Follistim. The new drug also seemed to cause more eggs to be released than the already-approved drug, although the clinical trial was only designed to test that the new drug wasn't worse than the old one. Its proven "non-inferiority" may not sound like much of an advantage, but the drug requires only one shot in the first seven days of treatment as opposed to daily doses of Follistim.

Corifollitropin alfa is part of the well-stocked pipeline that Schering got when it purchased Dutch Akzo Nobel's (Other OTC: AKZOY.PK) Organon BioSciences subsidiary. The purchase should begin to pay off in the not-too-distant future since both anesthesia reversal agent Bridion and antipsychotic asenapine are under FDA review.

Along with the pipeline, Schering acquired approved drugs, including Follistim, which managed $145 million in sales last quarter. That's not exactly blockbuster status, but if the idea of fewer injections pushes more women into fertility treatments, combined sales of Follistim and corifollitropin alfa could help move the drug category closer to that $1 billion, blockbuster status.

Just as Pfizer (NYSE: PFE  ) isn't going to replace $12.7 billion worth of Lipitor sales with a single drug when that goes off patent, Schering should plan on spreading any lost sales and growth from its cholesterol franchise among several replacements. If it manages that, investors will be proud parents.

So far, at least, its newest fertility treatment drug looks like a nice addition to the family.

Will Schering-Plough be able to come back? That's the kind of question answered at our Inside Value newsletter. To see which companies have been judged able to do so, take a free 30-day trial. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is both an Income Investor and an Inside Value recommendation.The Fool's disclosure policy doesn't like needles, paper shredders, or other objects with sharp points.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 681132, ~/Articles/ArticleHandler.aspx, 9/20/2014 6:16:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 21 hours ago Sponsored by:
DOW 17,279.74 13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASD 4,579.79 -13.64 -0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/3/2009 4:02 PM
SGP.DL2 $28.15 Down +0.00 +0.00%
Schering-Plough Co… CAPS Rating: ****
MRK $60.49 Up +0.18 +0.30%
Merck & Co., Inc. CAPS Rating: ***
PFE $30.40 Down -0.18 -0.59%
Pfizer CAPS Rating: ****

Advertisement